Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A
lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Your browser is not supported
Switch to Chrome, Edge, Firefox or Safari
This advisory gives an overview of extended-release injectable naltrexone for people with opioid dependence. It discusses how it differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit.
This guide explains how to use extended-release injectable naltrexone as part of medication-assisted treatment (MAT) for opioid use disorder. It covers assessing patients, initiating MAT, monitoring progress, and deciding when to end treatment.
This guide informs clinicians about medications for opioid use disorder treatment, including side effects, drug interactions, and take-home doses. It discusses patient counseling, associated medical issues, hepatitis C evaluation, drug testing, and pregnant women.
This manual offers guidelines for medication-assisted treatment for people, particularly veterans, living with post-traumatic stress disorder and co-occurring opioid use disorders. It covers screening, concomitant treatment, pharmacotherapy, and multiple misused substances.
This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.
This advisory for behavioral health practitioners provides a brief overview of complementary health approaches. It describes the practices and products that are considered complementary, and explains how practitioners can help patients understand the benefits and risks.
This Advisory highlights how mental and substance use disorder treatment programs can better serve people with physical and cognitive disabilities and substance use disorders (SUDs) and/or serious mental illness (SMI).
